These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7905393)

  • 21. Structural elucidation of new urinary tamoxifen metabolites by liquid chromatography quadrupole time-of-flight mass spectrometry.
    Lu J; He C; He G; Wang X; Xu Y; Wu Y; Dong Y; Ouyang G
    J Mass Spectrom; 2014 Jul; 49(7):570-8. PubMed ID: 25044841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide.
    Lien EA; Anker G; Lønning PE; Solheim E; Ueland PM
    Cancer Res; 1990 Sep; 50(18):5851-7. PubMed ID: 2393854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts.
    Robinson SP; Langan-Fahey SM; Jordan VC
    Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1769-76. PubMed ID: 2632258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydrophilic interaction liquid chromatography-tandem mass spectrometry determination of estrogen conjugates in human urine.
    Qin F; Zhao YY; Sawyer MB; Li XF
    Anal Chem; 2008 May; 80(9):3404-11. PubMed ID: 18348576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and investigation of alpha-hydroxy-N,N-didesmethyltamoxifen as a proximate carcinogen in the metabolic activation of tamoxifen.
    Gamboa da Costa G; Marques MM; Freeman JP; Beland FA
    Chem Res Toxicol; 2003 Sep; 16(9):1090-8. PubMed ID: 12971796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient.
    Robinson SP; Langan-Fahey SM; Johnson DA; Jordan VC
    Drug Metab Dispos; 1991; 19(1):36-43. PubMed ID: 1673419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medication use, tamoxifen (TAM), and TAM metabolite concentrations in women with breast cancer.
    Gallicchio L; Tkaczuk K; Lord G; Danton M; Lewis LM; Lim CK; Flaws JA
    Cancer Lett; 2004 Jul; 211(1):57-67. PubMed ID: 15194217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The steady-state pharmacokinetics of tamoxifen and its metabolites in breast cancer patients.
    Soininen K; Kleimola T; Elomaa I; Salmo M; Rissanen P
    J Int Med Res; 1986; 14(3):162-5. PubMed ID: 3522312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantification of tamoxifen DNA adducts using on-line sample preparation and HPLC-electrospray ionization tandem mass spectrometry.
    Gamboa da Costa G; Marques MM; Beland FA; Freeman JP; Churchwell MI; Doerge DR
    Chem Res Toxicol; 2003 Mar; 16(3):357-66. PubMed ID: 12641436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative monitoring of tamoxifen in human plasma extended to 40 metabolites using liquid-chromatography high-resolution mass spectrometry: new investigation capabilities for clinical pharmacology.
    Dahmane E; Boccard J; Csajka C; Rudaz S; Décosterd L; Genin E; Duretz B; Bromirski M; Zaman K; Testa B; Rochat B
    Anal Bioanal Chem; 2014 Apr; 406(11):2627-40. PubMed ID: 24633563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer.
    Fabian C; Tilzer L; Sternson L
    Biopharm Drug Dispos; 1981; 2(4):381-90. PubMed ID: 7317574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS.
    Prakash C; Soliman V
    Drug Metab Dispos; 1997 Nov; 25(11):1288-97. PubMed ID: 9351906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Excretion of hydroxylated metabolites of tamoxifen in human bile and urine.
    Kisanga ER; Mellgren G; Lien EA
    Anticancer Res; 2005; 25(6C):4487-92. PubMed ID: 16334131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tamoxifen metabolite isomer separation and quantification by liquid chromatography-tandem mass spectrometry.
    Jaremko M; Kasai Y; Barginear MF; Raptis G; Desnick RJ; Yu C
    Anal Chem; 2010 Dec; 82(24):10186-93. PubMed ID: 21086978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride.
    Teichert J; Baumann F; Chao Q; Franklin C; Bailey B; Hennig L; Caca K; Schoppmeyer K; Patzak U; Preiss R
    Cancer Chemother Pharmacol; 2007 May; 59(6):759-70. PubMed ID: 16957931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct determination of nucleosides in the urine of patients with breast cancer using column-switching liquid chromatography-tandem mass spectrometry.
    Cho SH; Jung BH; Lee SH; Lee WY; Kong G; Chung BC
    Biomed Chromatogr; 2006 Nov; 20(11):1229-36. PubMed ID: 16799933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of tamoxifen and its metabolites in human plasma by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM).
    Murphy C; Fotsis T; Pantzar P; Adlercreutz H; Martin F
    J Steroid Biochem; 1987 May; 26(5):547-55. PubMed ID: 3586671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].
    Bachmann-Moisson N; Barberi-Heyob M; Merlin JL; Ledrich ML; Batt AM; Guillemin F
    Bull Cancer; 1996 Oct; 83(10):808-15. PubMed ID: 8952630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isobaric metabolite interferences and the requirement for close examination of raw data in addition to stringent chromatographic separations in liquid chromatography/tandem mass spectrometric analysis of drugs in biological matrix.
    Yan Z; Maher N; Torres R; Cotto C; Hastings B; Dasgupta M; Hyman R; Huebert N; Caldwell GW
    Rapid Commun Mass Spectrom; 2008 Jul; 22(13):2021-8. PubMed ID: 18512848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Confirmatory analysis for drugs of abuse in plasma and urine by high-performance liquid chromatography-tandem mass spectrometry with respect to criteria for compound identification.
    Maralikova B; Weinmann W
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Nov; 811(1):21-30. PubMed ID: 15458717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.